This HTML5 document contains 176 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://dx.doi.org/10.1038/
n10http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11https://scigraph.springernature.com/pub.10.1038/
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q37397995
rdf:type
wikibase:Item
schema:description
наукова стаття, опублікована в травні 2013 scientific article published on 14 May 2013 مقالة علمية نشرت في 14 مايو 2013 videnskabelig artikel article scientifique articolo scientifico article científic научни чланак bilimsel makale vedecký článok vetenskaplig artikel artículu científicu espublizáu en 2013 vědecký článek artigo científico wissenschaftlicher Artikel wetenschappelijk artikel
p:P577
wds:Q37397995-2CCFDB41-8B8B-4695-94E3-EA548EEAE2F5
wdt:P577
2013-05-14T00:00:00Z
p:P2888
wds:Q37397995-B42DAC91-4ED5-460B-836D-D89019A628DA
wdt:P2888
n11:leu.2013.152
p:P2860
wds:Q37397995-0802D6BD-12DE-4251-81B8-CDFC32DB13FF wds:Q37397995-0F05D510-D015-4880-B865-8BC4042BBA1A wds:Q37397995-1216C862-7178-4D3C-9B08-5DE2CDA65C69 wds:Q37397995-133D290C-DC31-4429-BA3F-58D5A23E36E0 wds:Q37397995-1CB3F43D-4173-445B-BAE0-6F5FBFE6D12C wds:Q37397995-2085493C-DD69-4922-9FF5-ECCBB0E9D2DD wds:Q37397995-229D1DAF-C543-4D5F-B479-3F3626E19C53 wds:Q37397995-4D95E702-CE94-4879-887D-8D4609F9CB09 wds:Q37397995-5018DAA1-4228-4925-9FEC-2DEEC10B1755 wds:Q37397995-5CDAE8EF-99BF-4554-9D0E-02ED0E90A684 wds:Q37397995-624B1361-1F0C-454F-9AD2-209D635E093E wds:Q37397995-65AC486F-E13D-42CC-A245-ECB21B1BA3FF wds:Q37397995-671D4E6B-2661-47DB-83B1-AD36633D3961 wds:Q37397995-67F4CB9A-0D09-4F2D-AF50-C263425C362F wds:Q37397995-6B50FD95-F24F-43E5-8118-660194B30C0B wds:Q37397995-6F0E691D-8432-4618-9B14-BB9A0DFBA5A4 wds:Q37397995-71B9F8FC-B5C8-4743-A9D7-50033256A810 wds:Q37397995-7C00D03C-6571-4A65-9033-CB0FBD16C42E wds:Q37397995-7C2AF3BB-CA17-4AE8-9D84-A11544C10028 wds:Q37397995-7D5B1D63-00FD-4334-860F-03067968D720 wds:Q37397995-8BBB6B1B-46E8-4D8E-993C-C393030E14AA wds:Q37397995-8FDAB97D-BC24-44D8-9C0F-29502CA7F474 wds:Q37397995-9422AB47-31F3-415A-BB16-25B697FF2C3F wds:Q37397995-9DF7AEEA-22AE-4025-B5A3-E52C8EE335B0 wds:Q37397995-AA20B65D-F0A7-4E7D-A269-A71D7353C7E1 wds:Q37397995-AA61B8D5-0C8F-4427-B8A3-95D79E44FA08 wds:Q37397995-BE9D7275-4282-4AFC-B79A-F7580F9696AB wds:Q37397995-C2297180-7598-4379-A293-2772FB37F130 wds:Q37397995-D322CFDB-688E-4B5F-B00D-CF67388792C1 wds:Q37397995-D9B89EEF-227C-4948-9069-AEADCFC3F513 wds:Q37397995-DA07EE07-1662-4F60-97A6-DC62C2BC4F8B wds:Q37397995-E3B715AF-41E9-45B8-9122-4D5FC1F621B2 wds:Q37397995-E59770EC-0D19-4309-91F5-543D5023ADA4 wds:Q37397995-E8353BD4-39FC-4821-8FEF-17B4179C2895 wds:Q37397995-ED63B458-3370-4E43-B9C2-648479BE2A09 wds:Q37397995-EE974478-29C2-4F05-BB69-FBE8395935AB wds:Q37397995-F7397C13-1296-4C7A-92EF-AC725A4134AB wds:Q37397995-F994AA28-A902-4534-BC7F-E0784FE4AB73
wdt:P2860
wd:Q34008600 wd:Q79345406 wd:Q34753416 wd:Q36848202 wd:Q37268930 wd:Q48025834 wd:Q33402536 wd:Q37028556 wd:Q38001913 wd:Q36910280 wd:Q47826998 wd:Q80332885 wd:Q42965343 wd:Q24647620 wd:Q83979410 wd:Q34549410 wd:Q46068547 wd:Q53127020 wd:Q34815786 wd:Q33401596 wd:Q33405602 wd:Q34291281 wd:Q43195076 wd:Q53243787 wd:Q37835572 wd:Q82907285 wd:Q42925566 wd:Q37753339 wd:Q37847667 wd:Q38094334 wd:Q34241661 wd:Q85048462 wd:Q33386052 wd:Q58455735 wd:Q37863993 wd:Q31094748 wd:Q36941047 wd:Q30571858
p:P2093
wds:Q37397995-22C0DE4D-8858-42D6-AA4A-3C28E6EA2956 wds:Q37397995-258A3A89-2E88-4CE7-B63A-AC45387CFCCF wds:Q37397995-4A33DD56-75EC-4284-A076-DCFB65155CF4 wds:Q37397995-40785D8F-9BC5-41BC-AB8A-C43E0E561E9F wds:Q37397995-428CD245-1111-4C02-93BB-BA56C66193D7 wds:Q37397995-3E636BED-0B8F-4E82-889D-2D0E54357331 wds:Q37397995-30A69779-26B7-4E55-864A-4D12337F00E2 wds:Q37397995-38947EAA-2D99-4C4B-AC89-C0F2ABE86E2B wds:Q37397995-1786E387-EB33-4513-AB66-B86E7261C569 wds:Q37397995-13362F63-0EC7-471C-A846-A4988F998D80 wds:Q37397995-11EAED7A-9820-4209-B175-06A89506E073 wds:Q37397995-0DA3F6F6-9D32-4064-B929-24C4EED72F10 wds:Q37397995-E270A029-1CE6-405E-9C5E-8BE600CFE701 wds:Q37397995-E0BF5377-401F-4415-BE7B-2AB41CE7F4C0 wds:Q37397995-D7C7362A-40A2-4978-9ACD-A29E8042B3C1 wds:Q37397995-E6943695-DB7D-4614-98FD-78EFFEBD8C66 wds:Q37397995-B9308960-ED58-459C-B7A9-8188A028E9BA wds:Q37397995-AC9BE7E4-E4F0-4ADA-B014-0255A292F6B5 wds:Q37397995-5C355BFD-4A5E-41C5-884A-C4779F684CCC wds:Q37397995-5550487C-C6B3-476E-87D1-F6B3DCD34312
wdt:P2093
M Wang N Bahlis M Alsina R Vij T Martin S Jagannath K Song A K Stewart R Z Orlowski A Chanan-Khan B L Harrison J Zonder A F Wong F J Reu S Trudel A J Jakubowiak G Somlo D S Siegel S Lonial V Kukreti
rdfs:label
Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study
skos:prefLabel
Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study
schema:name
Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study
p:P50
wds:Q37397995-0D5AA5FC-94AB-4FFF-9961-D2F0C096420B wds:Q37397995-C792956C-3D32-4162-8649-D213AF3CFEA7
wdt:P50
wd:Q85544110 wd:Q88774336
p:P1476
wds:Q37397995-54BC1CFE-FF6C-4900-BE2B-10CB2F7B72DB
wdt:P1476
Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study
p:P304
wds:Q37397995-06F8537D-1DE5-4A98-B0B5-51CA404D36FF
wdt:P304
2351-2356
p:P31
wds:Q37397995-204E9C03-0ED8-40AB-8136-E2BE730EC1EE
wdt:P31
wd:Q13442814
p:P921
wds:Q37397995-BA038E9C-F21F-4310-B3E5-973E3969B3D6 wds:Q37397995-3FB7072C-0038-41D6-B9FA-246DCC98A351
wdt:P921
wd:Q467635 wd:Q181600
p:P698
wds:Q37397995-D745F074-A36D-47AD-9341-3E5F324D4EDA
wdtn:P698
n10:23670297
wdt:P698
23670297
p:P1433
wds:Q37397995-C31A8ED7-032B-4047-93AD-F63020202252
wdt:P1433
wd:Q6534498
p:P433
wds:Q37397995-1777154D-0C8E-4C59-A49C-57E4D94FC770
p:P478
wds:Q37397995-580DB885-A1FD-4C59-84A1-A8B7A00A3D4A
wdt:P433
12
wdt:P478
27
p:P356
wds:Q37397995-26E0311D-444F-49E7-A1AD-ED2C2434A38A
wdtn:P356
n9:LEU.2013.152
wdt:P356
10.1038/LEU.2013.152
p:P5875
wds:Q37397995-78D21561-FBB4-4866-B1A5-894C8CC2AF06
wdt:P5875
236740190
p:P932
wds:Q37397995-73B5FBB3-F62A-4245-B64D-8B0D0147E0AB
wdt:P932
3865533